Anti-Rheumatic Drugs - Baltics | Statista Market Forecast

In 2024, the Anti-Rheumatic Drugs market in the Baltics is projected to reach a revenue of US$23.65m.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.05%, leading to a market volume of US$24.92m by 2029.
In comparison to other countries worldwide, United States is anticipated to generate the highest revenue in the market, amounting to US$34.70bn in 2024.
The demand for anti-rheumatic drugs in the Baltics has been steadily increasing due to the aging population and rising prevalence of rheumatic diseases.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Baltics has been experiencing steady growth in recent years, driven by several factors.

Customer preferences: Patients in Baltics are increasingly seeking out more effective and targeted treatments for rheumatic diseases, such as rheumatoid arthritis and lupus. This has led to a growing demand for biologic drugs, which are designed to specifically target the underlying causes of these diseases. Additionally, patients are increasingly seeking out more convenient and less invasive treatment options, such as self-administered injectable drugs.

Trends in the market: One major trend in the Anti-Rheumatic Drugs market in Baltics is the increasing use of biosimilars, which are lower-cost versions of biologic drugs. This has been driven in part by the growing availability of biosimilars in the region, as well as by efforts to reduce healthcare costs. Another trend is the growing use of combination therapies, which involve the use of multiple drugs to treat rheumatic diseases. This approach has been shown to be more effective than using a single drug alone.

Local special circumstances: One unique factor impacting the Anti-Rheumatic Drugs market in Baltics is the relatively low prevalence of rheumatic diseases in the region. This has led to a smaller market size compared to other regions, but also presents opportunities for growth as awareness of these diseases increases and more patients seek out treatment. Additionally, the region's healthcare systems are generally well-developed and provide good access to healthcare services, which has helped to support the growth of the Anti-Rheumatic Drugs market.

Underlying macroeconomic factors: The overall economic environment in Baltics has been relatively stable in recent years, which has helped to support growth in the Anti-Rheumatic Drugs market. Additionally, the region's aging population is driving demand for treatments for rheumatic diseases, as these conditions are more common among older adults. However, the region's relatively small market size and the presence of low-cost competitors could pose challenges for companies looking to enter or expand in the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.